Rambod Mehdi, Heine Gunnar H, Seiler Sarah, Dominic Elizabeth A, Rogacev Kyrill S, Dwivedi Rama, Ramezani Ali, Wing Maria R, Amdur Richard L, Fliser Danilo, Raj Dominic S
Department of Internal Medicine, Texas Tech University Health Sciences Center, Paul L. Foster School of Medicine, El Paso, TX, USA.
Saarland University Medical Center and Saarland University Faculty of Medicine, Internal Medicine IV - Nephrology and Hypertension, Homburg, Saar, Germany.
Atherosclerosis. 2014 Oct;236(2):360-5. doi: 10.1016/j.atherosclerosis.2014.07.026. Epub 2014 Aug 12.
Angiogenic cytokines fms-like tyrosine kinase-1(sFlt-1) and placental growth factor (PlGF) are associated with increased risk for cardiovascular disease (CVD) in the general population. In this study we examine the association between these vascular endothelial factors and atherosclerosis, cardiovascular outcome, and mortality in chronic kidney disease (CKD) patients.
Serum level of PlGF and sFlt-1 were measured in 301 patients with CKD, who were followed for up to 4 years. Primary outcomes were CV events and all-cause mortality. Carotid-intima media thickness (CIMT) was used as marker of atherosclerosis. Kaplan-Meier survival curves and the Cox proportional hazard model were used to assess the association of biomarkers and clinical outcomes.
Mean (SD) PlGF and sFlt-1 were 5.45 ng/ml (3.76) and 68.6 (28.0) pg/ml, respectively. During the follow up time, 60 patients (19.9%) experienced CV events and 22 patients (7.3%) died. Compared with low PlGF, patients with PlGF above median level had higher CV events (12.7% vs. 27.2%, p = 0.002) and mortality (2.0% vs. 12.6%, p < 0.001). The associations of PlGF and sFlt-1 with CV events were not statistically significant in the fully adjusted model. Higher PlGF was associated with greater death risk (HR = 5.22, 95% CI: 1.49-18.33, p = 0.01), which was robust to adjustment for sFlt-1 and other risk factors. Elevated sFlt-1 level was also an independent predictor of mortality (HR 3.41, 95% CI: 1.49-9.51, p = 0.019).
In CKD patients not yet on dialysis, higher serum level of PlGF and sFlt-1 are associated with increased mortality, but not CV events.
血管生成细胞因子类fms样酪氨酸激酶-1(sFlt-1)和胎盘生长因子(PlGF)与普通人群中心血管疾病(CVD)风险增加相关。在本研究中,我们探讨了这些血管内皮因子与慢性肾脏病(CKD)患者动脉粥样硬化、心血管结局及死亡率之间的关联。
检测了301例CKD患者的血清PlGF和sFlt-1水平,并对其进行了长达4年的随访。主要结局为心血管事件和全因死亡率。颈动脉内膜中层厚度(CIMT)用作动脉粥样硬化的标志物。采用Kaplan-Meier生存曲线和Cox比例风险模型评估生物标志物与临床结局之间的关联。
PlGF和sFlt-1的平均(标准差)水平分别为5.45 ng/ml(3.76)和68.6(28.0)pg/ml。在随访期间,60例患者(19.9%)发生心血管事件,22例患者(7.3%)死亡。与PlGF水平较低的患者相比,PlGF高于中位数水平的患者发生心血管事件的比例更高(12.7%对27.2%,p = 0.002),死亡率也更高(2.0%对12.6%,p < 0.001)。在完全调整模型中,PlGF和sFlt-1与心血管事件之间的关联无统计学意义。较高的PlGF与更高的死亡风险相关(风险比[HR]=5.22,95%置信区间[CI]:1.49 - 18.33,p = 0.01),在对sFlt-1和其他风险因素进行调整后该关联依然显著。sFlt-1水平升高也是死亡率的独立预测因素(HR 3.41,95% CI:1.49 - 9.51,p = 0.019)。
在尚未接受透析的CKD患者中,较高的血清PlGF和sFlt-1水平与死亡率增加相关,但与心血管事件无关。